On this week’s episode of Biotech Hangout, hosts Chris Garabedian, Bruce Booth, Josh Schimmer, Eric Schmidt and Sam Fazeli start the show on the topic of M&A and ponder “where are the deals?” as they consider potential
reasons such as the U.S. election, too few assets or too few buyers. The conversation turns to the venture funding environment with a preview of the third quarter venture funding numbers. On the theme of stock price reactions,
the group digs into why Sarepta’s has dropped despite its gene therapy now fully approved and discusses Soleno’s stock jump on the news from regulators to not hold an advisory meeting over its new drug application. In other news, the group highlights another China deal, this time between AstraZeneca and CSPS Pharma for a pre-clinical novel lipid-lowering therapy. The hosts also discuss the
move by Lily to go after the compounding pharmacies, GSK agrees to settle Zantac lawsuits and the latest on Pfizer and Starboard which leads to a broader discussion on activism in biopharma. Regarding data, the hosts cover GSK’s RSV data, Scholar Rock’s spinal muscular atrophy data, among other topics. *This episode aired on October 11, 2024.